Cilta-cel Boosts Overall Survival in New Early Line Multiple Myeloma Data
Johnson & Johnson subsidiary Janssen’s and Legend Biotech's ciltacabtagene autoleucel (cilta-cel; marketed as Carvykti) an FDA-approved BCMA-directed autologous chimeric antigen receptor T-cell (CAR-T) therapy, has produced significantly improved …